

Famke L Schneiders

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4887136/publications.pdf>

Version: 2024-02-01

17
papers

380
citations

1163117

8
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

638
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period. <i>Radiotherapy and Oncology</i> , 2022, 170, 165-168.	0.6	9
2	Developments in radiation techniques for thoracic malignancies. <i>European Respiratory Review</i> , 2021, 30, 200224.	7.1	6
3	Finding the Goldilocks zone in neoadjuvant radioimmunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 545-546.	27.6	2
4	Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 20, 1-4.	2.9	1
5	Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy. <i>Radiotherapy and Oncology</i> , 2021, 163, 14-20.	0.6	10
6	Changes in gastric anatomy after delivery of breath-hold MR-guided SABR for adrenal metastases. <i>Radiotherapy and Oncology</i> , 2020, 152, 26-29.	0.6	7
7	Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. <i>BMC Cancer</i> , 2020, 20, 764.	2.6	18
8	The effects of systemic treatment with aminobisphosphonates and statins on circulating VÎ³9VÎ²2-T cells in patients with advanced cancer. <i>Immunobiology</i> , 2018, 223, 171-177.	1.9	4
9	A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of VÎ³9VÎ²2-T cells. <i>Onc Immunology</i> , 2018, 7, e1375641.	4.6	61
10	Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells. <i>Clinical Immunology</i> , 2015, 158, 92-99.	3.2	2
11	Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141+ Dendritic Cells and Enhanced Cross-Presentation. <i>Cancer Immunology Research</i> , 2015, 3, 495-505.	3.4	50
12	mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells. <i>Journal of Immunology</i> , 2015, 195, 2038-2045.	0.8	23
13	VÎ³9VÎ²2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy. <i>Onc Immunology</i> , 2014, 3, e955343.	4.6	1
14	Bispecific antibody platforms for cancer immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 153-165.	4.4	78
15	Activated iNKT cells promote VÎ³9VÎ²2-T cell anti-tumor effector functions through the production of TNF-Î±. <i>Clinical Immunology</i> , 2012, 142, 194-200.	3.2	16
16	Clinical experience with Î±-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. <i>Clinical Immunology</i> , 2011, 140, 130-141.	3.2	87
17	Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. <i>Medical Oncology</i> , 2011, 28, 1136-1139.	2.5	5